“Active surveillance … how to do it right”

Many readers, and particularly many support group leaders and other educators, may want to read and retain a copy of this very recent article in Oncology. … READ MORE …

Active surveillance in men with higher-risk forms of localized prostate cancer

The abstract of a paper currently in press in the Journal of Urology has offered us some potentially fascinating insight into the comparative outcomes of patients with low- and higher-risk forms of localized prostate cancer when they are initially managed on active surveillance. … READ MORE …

Informing the media community about prostate cancer and its management

A new article on the HealthNewsReview web site addresses issues related to the diagnosis of prostate cancer and the management of low-risk forms of the disease using active surveillance. … READ MORE …

Genetics, PSA, and steps toward a better prostate cancer risk management strategy

A new analysis of a large data set compiled by Kaiser Permanente suggests that combining PSA data with genetic risk data may offer a much more effective way to assess risk for clinically significant prostate cancer. … READ MORE …

Population-based rates of treatment for prostate cancer: 2007-2012

The population-based rate of Medicare patients getting treatment for prostate cancer dropped by 42 percent from 2007 to 2012 … but this drop did not occur in patients who had a high risk of dying from a cause other than prostate cancer within 10 years, who are arguably among those who least need immediate treatment for prostate cancer (and especially for low-risk forms of prostate cancer). … READ MORE …

Management of men with bone metastasis over time

A new review article in issue 2 of Everyday Urology addresses the topic of bone mets, quality of life, and related factors in the management of advanced and metastatic prostate cancer over time. … READ MORE …

The cost and the effectiveness of genomic testing for prostate cancer risk

As regular readers will be well aware, there are now several different tests available that can be used to assess risk for low- and very low-risk forms of prostate cancer at time of diagnosis (as opposed to clinically significant forms that need early treatment). … READ MORE …